Skip to main content
SpringerLink
Log in

Response to the letter to the editors by Ottaiano et al.: “Cetuximab-dependent ADCC in cancer: dream or reality?”

  • Letter to the editor
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Division of Head and Neck Surgery, Departments of Otolaryngology and of Immunology, University of Pittsburgh Cancer Institute, Hillman Research Wing, 5117 Centre Avenue, Room 2.26, Pittsburgh, PA, 15213, USA

    Robert L. Ferris

  2. Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, USA

    Robert L. Ferris & Soldano Ferrone

Authors
  1. Robert L. Ferris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soldano Ferrone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert L. Ferris.

Additional information

Please note that we are simultaneously publishing a letter by Ottaiano et al., which is a response to the paper by López-Albaitero et al., published in 2009 (Cancer Immunol Immunother 58:1853–1862), and a response by Ferris and Ferrone to the Ottaiano letter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferris, R.L., Ferrone, S. Response to the letter to the editors by Ottaiano et al.: “Cetuximab-dependent ADCC in cancer: dream or reality?”. Cancer Immunol Immunother 59, 1609–1610 (2010). https://doi.org/10.1007/s00262-010-0885-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-010-0885-2

Keywords

Search

Navigation